Introduction
Minimally differentiated acute myeloblastic leukemia (AML), now classified as M0 AML, is a rare type of AML associated with poor prognosis [1] [2] . Recently, we and others reported in M0
AML a high frequency of mutations of AML1 gene, a gene which plays a pivotal role in myeloid differentiation [3] [4] [5] [6] . In this multicenter cooperative work, we analysed clinical and biological characteristics of a large series of M0AML and compared, in particular, patients with and without AML1 mutation.
Patients and methods

Patient population
Fifty nine patients diagnosed as de novo M0 AML between 1993 and 2000 in the Hematology departments of 9 French university hospitals (Besançon, Bordeaux, Dijon, Lille, Marseille, Nantes, Paris, Reims and Toulouse) were included. All cases were centrally reviewed by members of the GFHC for cytology, cytochemistry and immunophenotyping, and members of the GFCH for cytogenetic findings.
Patients with older age and/or poor clinical condition received supportive care only or moderate chemotherapy (table1). Other patients received anthracyclin-AraC induction chemotherapy based on European or French multicenter protocols for AML (ALFA, BGMT, EORTC and GOELAMS cooperative groups) [7] [8] [9] [10] . Patients who achieved CR received consolidation with high dose AraC based chemotherapy, autologous or allogeneic stem cell transplantation depending on age, donor availability and trial design.
Morphological studies
Bone marrow and peripheral blood smears were stained by May-Grünwald-Giemsa.
Myeloperoxidase, naphtol AS-D-acetate esterases with and without fluoride inhibition, or naphthyl acetate butyrate esterases cytochemical reactions were performed.
Immunophenotypic studies
Immunophenotyping was performed by flow cytometry. Membrane expression of : CD 2, 3, 5, 7, 10, 19, 20, 22, 24, 79a, 34, 13, 33, 117, 14, 15, 41, 61, 65 and HLADR was tested. For CD 3, 13, 22 and MPO, intracytoplasmic antigen expression was also tested. Diagnostic criteria of M0 AML were : (i) < 3% myeloperoxydase positive blasts, (ii) expression of at least one of the following myeloid markers: CD13, CD33 or MPO, (iii) no expression of lymphoid markers except CD4 or CD7 (EGIL criteria) 11 .
Cytogenetic and fluorescence in situ hybridization (FISH) studies
For conventional cytogenetic analysis, chromosomes were identified by RHG and/or GTG banding and abnormalities described according to ISCN nomenclature (1995) 12 . FISH was performed according to standard methods and manufacturer's instructions using whole chromosomes or locus specific probe MLL, AML1 (Vysis, Downer-grooves, Ill) and YACs probes for AF10, CALM and ETV6 regions obtained from the CEPH (Paris) (815c7, 814d9, 936e2).
Molecular studies
Detection of AML1 mutations was made on DNA and/or cDNA from bone marrow cells, as previously reported 3, 6 . 
Result and Discussion
Clinical, biological characteristics and outcome.
Clinical and hematological findings are summarized in (fig 2A) . Those results confirmed the poor prognosis of M0 AML, due besides frequent chromosomal rearrangements to the older age of many patients, who could not receive intensive chemotherapy 2, 19, 24 .
The poor prognosis of FLT3 duplication in other AML as a whole is now well documented 25 . Here, in M0 patients treated intensively, FLT3 duplication was the only prognostic factor with a median survival 9 months in patients with FLT3 duplication versus 16 months in patients without FLT3 duplication (p=0.05) ( fig 2C) .
AML1 mutation in the M0AML population
AML1 mutation was found in 16 patients (27%) (table 2), an incidence similar to that observed in previous reports [3] [4] [5] [6] . All mutations, involved the RUNT domain, were missense (n=7) or stop codon mutation (n=15), were biallelic (except one case) therefore probably inactivating AML1 protein. Those characteristics are similar to our preliminary results and show the strong correlation between lack of AML1 function and M0 FAB subtype 26 .
In our M0 AML series, no differences were found between patients with or without AML1 mutations for age, sex, platelet count, Hb value, myelodysplastic features, response to chemotherapy and survival (table 2) . On the other hand, patients with AML1 mutation showed significantly higher leukocyte counts, and higher marrow blast percentage, suggesting that AML1 mutations are associated with greater cell proliferation, lower incidence of CD33 and higher incidence of HLA DR expression and IgH or TCR genes. There was also a trend for lower incidence of chromosomal abnormalities and complex chromosomal abnormalities in our M0
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